Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Clinical trial NCT03631836 · UNKNOWN
Trial details
- NCT number
- NCT03631836
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-01
- Primary completion
- 2022-01-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.